About ReproCELL
ReproCELL is a company based in Osaka (Japan) founded in 2003.. The company has 99 employees as of March 31, 2024. ReproCELL has completed 4 acquisitions, including BioServe Biotechnologies, Biopta and Reinnervate. ReproCELL operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Osaka, Japan
- Employees 99 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Reprocell Inc.
-
Annual Revenue
$18.99 M (USD)22.74as on Mar 31, 2024
-
Net Profit
$657.85 K (USD)428.72as on Mar 31, 2024
-
EBITDA
$-507.81 K (USD)78.58as on Mar 31, 2024
-
Latest Funding Round
$292.58 K (USD), Grant
Oct 25, 2019
-
Investors
Maryland Stem Cell Research Fund
& 1 more
-
Employee Count
99
as on Mar 31, 2024
-
Investments & Acquisitions
BioServe Biotechnologies
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ReproCELL
ReproCELL is a publicly listed company on the TSE with ticker symbol 4978 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of ReproCELL
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $292,580
- First Round First Round
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2019 | Amount | Grant - ReproCELL | Valuation |
investors |
|
| Nov, 2006 | Amount | Seed - ReproCELL | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ReproCELL
ReproCELL has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Maryland Stem Cell Research Fund and SBI Investment. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stem cell research startups in healthcare are funded and accelerated.
|
Founded Year | Domain | Location | |
|
Venture capital funds are managed to support unlisted companies' growth.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ReproCELL
ReproCELL has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include BioServe Biotechnologies, Biopta and Reinnervate. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Products and services for stem cell research are supplied.
|
2008 | ||||
|
DNA synthesis, sequencing, extraction, and biomarker discovery services are provided.
|
2002 | ||||
|
Fresh human tissues are utilized in drug development research.
|
2002 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - ReproCELL
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Reprocell Comparisons
Competitors of ReproCELL
ReproCELL operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Reprocell
Frequently Asked Questions about ReproCELL
When was ReproCELL founded?
ReproCELL was founded in 2003 and raised its 1st funding round 3 years after it was founded.
Where is ReproCELL located?
ReproCELL is headquartered in Osaka, Japan. It is registered at Osaka, Osaka Prefecture, Japan.
How many employees does ReproCELL have?
As of Mar 31, 2024, the latest employee count at ReproCELL is 99.
What is the annual revenue of ReproCELL?
Annual revenue of ReproCELL is $18.99M as on Mar 31, 2024.
What does ReproCELL do?
ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the worlds first human iPS cell products in 2009 and with the worlds most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK) and BioServe (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.
Who are the top competitors of ReproCELL?
ReproCELL's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Is ReproCELL publicly traded?
Yes, ReproCELL is publicly traded on TSE under the ticker symbol 4978.
How many acquisitions has ReproCELL made?
ReproCELL has made 4 acquisitions, including BioServe Biotechnologies, Biopta, and Reinnervate.
Who are ReproCELL's investors?
ReproCELL has 2 investors. Key investors include Maryland Stem Cell Research Fund, and SBI Investment.
What is ReproCELL's ticker symbol?
The ticker symbol of ReproCELL is 4978 on TSE.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.